Please ensure Javascript is enabled for purposes of website accessibility Horizon Biotechnology Fund - Janus Henderson Investors - Europe PA Belgium
{{banner.link_text}}
For financial professionals in Belgium

Horizon Biotechnology Fund

A fund investing in innovative companies addressing high unmet medical needs or improving the standard of care in the fast-growing biotechnology sector.

ISIN
LU1897414303

NAV
USD 24.49
As of 27/12/2024

1-Day Change
USD 0.47 (1.96%)
 As of 27/12/2024

Morningstar Rating

As of 30/11/2024

Overview

Quarterly Update

Watch the investment team recap this quarter.

(Note: Filmed in October 2024).

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.
Performance target: To outperform the NASDAQ Biotechnology Total Return Index by 2% per annum, before the deduction of charges, over any 5 year period.

More

The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, of any size, including smaller capitalisation companies, in any country.
The Fund may also invest in other assets including bonds (including convertible bonds), preference shares, cash and money market instruments.
The Investment Manager may use derivatives (complex financial instruments) with the aim of making investment gains in line with the Fund's objective, to reduce risk or to manage the Fund more efficiently.
The Fund is actively managed with reference to the NASDAQ Biotechnology Total Return Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund's performance target and the level above which performance fees may be charged (if applicable). The Investment Manager has discretion to choose investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index.

Less

The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.
Potential investors must read the prospectus, and where relevant, the key investor information document before investing.
This website is a Marketing Communication and does not qualify as an investment recommendation.

ABOUT THIS FUND

Experienced and Specialised Investment Team: Dedicated biotechnology specialists with deep scientific backgrounds and a distinguished record of investing in biotechnology stocks. This highly specialised team is supported by the larger Janus Henderson health care team with over a century of combined health care investing experience.

Differentiated Fundamental Research: Seek to understand the science and the business to identify opportunities and mitigate the clinical and commercial risks inherent in the sector.

Disciplined Investment Process: Balanced across development stage, early commercial and profitable biotechnology companies and augmented by a differentiated Value at Risk Framework designed to mitigate the volatility associated with drug development.

Past performance does not predict future returns. 
 

RATINGS AND AWARDS

Lipper Fund Awards based on Horizon Biotechnology A2 USD shares only. Availability of this share class may be limited by law in certain jurisdictions. Performance records are detailed on the specific KID, fees and charges may vary and further information can be found in the fund’s prospectus and KID which must be reviewed before investing. Please consult your local sales representative if you have any further queries.

TOP HOLDINGS

Top holdings can be found in the factsheet of the fund.

Portfolio Management

Andy Acker, CFA
Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA
Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Agustin Mohedas, Ph.D.
Agustin Mohedas, Ph.D.

Portfolio Manager | Research Analyst

Industry since 2014.

Performance

Past performance does not predict future returns. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.
Cumulative & Annualised Performance (%)
As of 30/11/2024
A2 USD (Net) NASDAQ Biotechnology Total Return Sector Equity Biotechnology - OE
  
  Cumulative Annualised
1MO YTD 1YR 3YR 5YR 10YR Since Inception
10/12/2018
A2 USD (Net) -1.81 17.38 35.69 12.50 17.39 - 17.75
NASDAQ Biotechnology Total Return -0.03 7.05 20.87 -0.20 5.13 - 6.82
Sector Equity Biotechnology - OE 0.09 3.01 16.84 -3.60 1.59 - 3.56
 
  Annualised
3YR 5YR 10YR Since Inception
10/12/2018
A2 USD (Gross) - 21.32 - 21.70
NASDAQ Biotechnology Total Return + 2.00% - 7.23 - 8.96
Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk.  Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations.
Performance fees are charged separately as a way of rewarding the investment manager for superior returns or for outperforming specified targets. A Performance Fee is accrued where the NAV outperforms the relevant Hurdle NAV (subject to a High Water Mark).
Performance/performance target related data will display only when relevant to the fund/share class inception date and the annualised target time period.
Performance fees may be charged before the Fund’s outperformance target is reached.
© Morningstar 2024. All rights reserved. NAV-NAV, gross income reinvested where applicable.
Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time.
The ongoing charges includes fees payable to Distributors. Where the ongoing charges exceed the target outperformance relative to the benchmark the return is likely to be below the benchmark return, even when the Fund’s outperformance target (before the deduction of charges) has been achieved.
Calendar Year Returns (%)
As of 30/09/2024
A2 USD (Net) NASDAQ Biotechnology Total Return Sector Equity Biotechnology - OE
YTD 2023 2022 2021 2020 2019 Performance Inception
10/12/2018
A2 USD (Net) 19.90 23.28 -3.78 -5.17 61.32 34.70 -7.50
NASDAQ Biotechnology Total Return 9.79 4.59 -10.12 0.02 26.42 25.11 -6.85
Sector Equity Biotechnology - OE 4.70 5.25 -17.17 -7.68 27.50 25.36 -7.02
Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk.  Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations.
Performance fees are charged separately as a way of rewarding the investment manager for superior returns or for outperforming specified targets. A Performance Fee is accrued where the NAV outperforms the relevant Hurdle NAV (subject to a High Water Mark).
Performance/performance target related data will display only when relevant to the fund/share class inception date and the annualised target time period.
Performance fees may be charged before the Fund’s outperformance target is reached.
© Morningstar 2024. All rights reserved. NAV-NAV, gross income reinvested where applicable.
Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time.
The ongoing charges includes fees payable to Distributors. Where the ongoing charges exceed the target outperformance relative to the benchmark the return is likely to be below the benchmark return, even when the Fund’s outperformance target (before the deduction of charges) has been achieved.
Please note the performance target is to be achieved over a specific annualised time period. Refer to the performance target wording within the objective.

Recommended holding period 5 Years

Example Investment: USD 10,000

Scenarios If you exit after 1 year If you exit after 5 years
MinimumThere is no minimum guaranteed return. You could lose some or all of your investment
StressWhat you might get back after costs2,840 USD1,750 USD
Average return each year-71.59%-29.40%
UnfavourableWhat you might get back after costs6,410 USD9,500 USD
Average return each year-35.86%-1.02%
ModerateWhat you might get back after costs10,520 USD15,700 USD
Average return each year5.24%9.44%
FavourableWhat you might get back after costs17,240 USD24,330 USD
Average return each year72.37%19.46%
This chart shows the fund’s performance as the percentage loss or gain per year over the last 6 years against its benchmark. It can help you to assess how the fund has been managed in the past and compare it to its benchmark.

As of 30/09/2024
A2 USD (Net) NASDAQ Biotechnology Total Return Sector Equity Biotechnology - OE
Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk.  Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations.
Past performance does not predict future returns. The value of an investment may go down as well as up and you may lose the amount originally invested. Markets could develop very differently in the future. It can help you to assess how the fund has been managed in the past.
© Morningstar 2024. All rights reserved. NAV-NAV, gross income reinvested where applicable.
Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time.
Fee Information
Initial Charge 5.00%
Annual Charge 1.20%
Ongoing Charge
(As of 30/06/2023) 		1.89%
Performance Fee 20% of the 'Relevant Amount'
Hurdle Rate NASDAQ Biotechnology Total Return Index
For more information about charges, please see our fund charges page or the “charges” section of the fund’s prospectus.

Documents

Related Insights

Our intellectual capital is readily available and central to our Knowledge Shared approach"
Related Insights
Healthcare stocks shine in a dimming economy
3 Oct 2024
Timely & Topical

Healthcare stocks shine in a dimming economy

The sector’s traditionally defensive qualities and accelerating innovation could stand out amid a potentially slowing economy.

8 min read

Shaping a Brighter Future: AI’s impact on healthcare
10 Sep 2024
Timely & Topical

Shaping a Brighter Future: AI’s impact on healthcare

Hear how AI and other advances in healthcare are transforming patient outcomes and leading to new investment opportunities.

7 min read

Will a new candidate create volatility for healthcare stocks?
27 Aug 2024
Timely & Topical

Will a new candidate create volatility for healthcare stocks?

Why we do not expect the last-minute change in the U.S. presidential election to lead to heightened volatility in healthcare stocks.

4 min read

  • The value of the Funds and the income from them is not guaranteed and may fall as well as rise. You may get back less than you originally invested.
  • Past performance does not predict future returns.
  • Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.
  • Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
  • The Fund may use derivatives to help achieve its investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses to the Fund may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. mitigated by taking an offsetting position in a related security), the value of your investment may be impacted by changes in exchange rates.
  • When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies.
  • Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.
  • The Fund may incur a higher level of transaction costs as a result of investing in less actively traded or less developed markets compared to a fund that invests in more active/developed markets.
  • The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.
  • Funds incur costs as a necessary part of buying and selling the underlying investments, these are otherwise known as portfolio transaction costs, and include charges such as broker commission and Stamp Duty.
  • Before investing in any of our funds you should satisfy yourself as to the suitability and the risks involved.
  • Summary of Investor rights
  • Janus Henderson Investors Europe S.A. may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation.
  • Information on compliance with EU Sustainability related disclosures can be found here.
  • For detailed product information including the risks associated with investing please read the relevant Prospectus or Annual Report. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.
  • The Legal Entity Identifier for this product is 213800AV3O5CVAEQM982.

Choose region

Country

Language

What type of investor are you?